AGN 191701

retinoid X receptors agonist; RN refers to (E)-isomer; structure given in first source

Also Known As:

2-(2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)propen-1-yl)-4-thiophenecarboxylic acid; 5-(2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl)-3-thiophenecarboxylic acid; AGN-191701

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - AGN 191701: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - AGN 191701: 3

Experts

1.	Beard, R L: 1 article (12/2001)
2.	Chandraratna, R A: 1 article (12/2001)
3.	Escobar, M: 1 article (12/2001)
4.	Standeven, A M: 1 article (12/2001)
5.	Thacher, S M: 1 article (12/2001)
6.	Vuligonda, V: 1 article (12/2001)
7.	Yuan, Y D: 1 article (12/2001)

Related Diseases

1.	Hypertriglyceridemia 10/01/1996 - "Two RXR-selective agonists, LG100268 and AGN 191701, failed to induce hypertriglyceridemia or weight loss up to the highest doses tested. " 12/01/2001 - "We have now demonstrated that hypertriglyceridemia induced by an RAR agonist, AGN 190121 [4-[4-(2',6',6'-trimethylcyclohex-1-enyl)-but-1-yne-3-enyl]benzoic acid], is substantially potentiated by the RXR-selective agonists AGN 191701 [(E) 2-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)propen-1-yl]-4-thiophene-carboxylic acid] and AGN 192849 [(3,5,5,8,8,-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl) (5 carboxypyrid-2-yl)sulfide] in a dose-dependent manner. "
2.	Weight Loss (Weight Reduction) 10/01/1996 - "Two RXR-selective agonists, LG100268 and AGN 191701, failed to induce hypertriglyceridemia or weight loss up to the highest doses tested. "
3.	Necrosis 08/15/1997 - "AGN 191701 caused dose-dependent hepatomegaly in the absence of hepatic necrosis and necrosis and increased hepatocyte BrdU labeling index (LI). "
4.	Hyperplasia 08/15/1997 - "To determine if AGN 191701-induced hepatic hyperplasia was sustained, rats were treated by gavage with 60 mumol/kg of AGN 191701 for up to 7 days and exposed to BrdU via osmotic pump on days 1-3 or on days 6-8. Hepatocyte L1 and mitotic index were increased only in rats exposed to BrdU on days 1-3, indicating that AGN 191701-induced hepatocyte proliferation was transient. "
5.	Hepatomegaly 08/15/1997 - "AGN 191701 caused dose-dependent hepatomegaly in the absence of hepatic necrosis and necrosis and increased hepatocyte BrdU labeling index (LI). " 08/15/1997 - "(E)-2-[2-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl) propen-1-yl]-4-thiophenecarboxylic acid (AGN 191701) and other retinoid X receptor (RXR)-selective agonists were observed to cause hepatomegaly in rats. "

Related Drugs and Biologics

1.	Retinoid X Receptors (Retinoid X Receptor)
2.	Benzoic Acid (Potassium Benzoate)
3.	Thiophenes
4.	Sulfides (Thioethers)
5.	Carboxylic Acids
6.	Bromodeoxyuridine (BrdU)
7.	Acids
8.	(3,5,5,8,8,- pentamethyl- 5,6,7,8- tetrahydronaphthalen- 2- yl) (5 carboxypyrid-2-yl)sulfide
9.	AGN 190121
10.	LG 100268